Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism.
about
Optimal management of bone mineral disorders in chronic kidney disease and end stage renal diseaseMolecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease.A comparative study of bone biopsies from the iliac crest, the tibial bone, and the lumbar spine.A case report of severe calciphylaxis - suggested approach for diagnosis and treatment.A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM)Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism.Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.Supplementary searches of PubMed to improve currency of MEDLINE and MEDLINE In-Process searches via Ovid.Emerging drugs for secondary hyperparathyroidism.Cinacalcet and Clinical Outcomes in Dialysis.Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures.Management of secondary hyperparathyroidism: how and why?Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.Etelcalcetide for the treatment of secondary hyperparathyroidism.Evaluation of fracture risk in chronic kidney disease.Circulating markers of bone turnover.New approach in evaluation of ceramic-polymer composite bioactivity and biocompatibility.Variations of parathyroid hormone and bone biomarkers are concordant only after a long term follow-up in hemodialyzed patients.Total parathyroidectomy with forearm auto-transplantation improves the quality of life and reduces the recurrence of secondary hyperparathyroidism in chronic kidney disease patients.Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism.Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes.Effect of Cinacalcet Combined with Calcitriol on the Clinical Outcome and Bone Metabolism in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism.Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients.Is there a practical role for bone biopsy in chronic kidney disease?Impaired Citric Acid Cycle in Nondiabetic Chronic Kidney Disease.Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy.Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).Rethinking Bone Disease in Kidney Disease
P2860
Q28072340-C6EF8E86-1EFC-4098-93FC-537A13FCBAD6Q30234751-085C67A1-3B28-48E5-B978-AEC6F2EAD3EFQ30313255-14467D70-A249-4D2C-A069-0C23B943FF43Q30353115-4491E3C0-B2DB-46AE-B026-A075D047648BQ35682192-4FF39C8F-5459-439C-9ACB-465A06614584Q36193227-07020F33-2CAB-4D5C-AB3D-59D4623380ACQ36432849-AC60DABB-37FE-4483-97FD-A1FC8CE762DDQ37365243-A39701A9-A967-405C-95BD-57B9D2DA557AQ38363615-C7E2E01C-F129-467C-90B0-EF8187C9F030Q38565049-A0FC0462-002E-4803-A913-426B7CBC9BBBQ38576402-37155475-C9B8-4220-9E2E-A6F02D56C010Q38775426-4CD8B03A-F039-453C-83AB-D66F7BA544B3Q38828618-5E253D0E-B2D8-4384-9663-61CF8B123EB1Q39170853-FFF803AE-EC9A-491D-931C-A8AD19CE9EE5Q39225909-EDA45FC7-6A14-46A2-8B6D-EF70D3DD7248Q39304775-0BE52EA9-C7D5-4899-90B9-24D0BFF1576AQ41606384-C8D163D2-1BBA-4617-8004-8A945FE4755FQ42282597-5E2A87A7-6188-4528-AD4B-558A23590453Q47547825-B7AD68AC-F325-4640-9E26-35CD33975D73Q47549937-DEF6EE6D-185D-4D1C-8E30-7D89B87B2F0DQ49166621-600EEF97-E517-4521-9C84-2CDC1EF860D3Q50026683-7F1FD18B-596D-4671-810A-6355182A6636Q50034239-7830DDAE-728A-4497-9077-B164B6B01E04Q50711763-C9562C1C-8557-4139-AA9B-6E6FBB03B7D1Q55271991-62B199F5-45F4-4AAE-BFE7-1C1C3BE2793BQ55413395-3CF5E94D-17BD-4F05-848C-E36087D91ADBQ55476982-9D4059FE-2662-4FDE-8B40-E217E1A9F36AQ59126536-D14ED497-05C8-4867-A01F-3A72FCA696A7
P2860
Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Bone histomorphometry before a ...... secondary hyperparathyroidism.
@ast
Bone histomorphometry before a ...... secondary hyperparathyroidism.
@en
type
label
Bone histomorphometry before a ...... secondary hyperparathyroidism.
@ast
Bone histomorphometry before a ...... secondary hyperparathyroidism.
@en
prefLabel
Bone histomorphometry before a ...... secondary hyperparathyroidism.
@ast
Bone histomorphometry before a ...... secondary hyperparathyroidism.
@en
P2093
P2860
P356
P1433
P1476
Bone histomorphometry before a ...... secondary hyperparathyroidism.
@en
P2093
David M Spiegel
Geert J Behets
Lulu R Sterling
Marc E De Broe
Patrick C D'Haese
William G Goodman
P2860
P2888
P304
P356
10.1038/KI.2014.349
P407
P577
2014-10-22T00:00:00Z
P5875
P6179
1021669620